These are exciting times for the AMPEL team. BioBuzz thought it was a great time to catch up with AMPEL’s Co-founder, President, and Chief Scientific Officer Dr. Amrie Grammer to discuss her founder’s journey and AMPEL’s promising future.
With many COVID-19 treatments now available, a simple blood test can show doctors the best route to take. Charlottesville’s AMPEL BioSolutions says it can predict and detect the severity of a COVID-19 infection, as well as how to help a patient through its new genomic test called CovGENE.
AMPEL BioSolutions announced a breakthrough in precision and personalized medicine that can detect and predict the severity of COVID-19 in patients while also determining the best treatment options for each specific case.
While the COVID pandemic is easing in some places, the CDC says it’s the third leading cause of death for the third year in a row. Now, a Virginia company says it’s got a test that will help doctors determine which patients are at greatest risk so they can prescribe the best treatment.
AMPEL BioSolutions today announced a breakthrough in precision and personalized medicine that can detect and predict the severity of COVID-19 in patients while also determining the best treatment options for each specific case. The company’s new approach, through a simple blood test, will ultimately accelerate the means of providing effective treatments to the right people at the right time and potentially stem the serious illness caused by SARS-CoV-2 infection that can lead to lung damage or death.
A genomic test being developed by a Charlottesville company can predict a patient’s risk of developing severe COVID-19, new research from UVA Health suggests. That information could help doctors identify patients at high risk for poor outcomes and quickly begin tailored treatment.